4basebio (LON:4BB) Stock Price Down 5.5% – Here’s What Happened

Posted by Tyrone Williams on Jul 30th, 2026

4basebio PLC (LON:4BB – Get Free Report) was down 5.5% during trading on Thursday . The stock traded as low as GBX 519.75 and last traded at GBX 519.75. Approximately 2 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 1,415 shares. The stock had previously closed at GBX 550.

Wall Street Analysts Forecast Growth

Separately, Royal Bank Of Canada lowered their price objective on shares of 4basebio from GBX 1,600 to GBX 1,400 and set an “outperform” rating on the stock in a research note on Monday, June 15th. One analyst has rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of GBX 1,400.

View Our Latest Stock Analysis on 4BB

4basebio Trading Down 5.5%

The firm has a market cap of £80.48 million, a P/E ratio of -4.77 and a beta of 1.09. The company’s 50 day moving average is GBX 523.47 and its two-hundred day moving average is GBX 525.29. The company has a debt-to-equity ratio of 201.47, a current ratio of 2.73 and a quick ratio of 3.52.

4basebio (LON:4BB – Get Free Report) last issued its quarterly earnings results on Wednesday, May 20th. The company reported GBX (1.09) earnings per share (EPS) for the quarter. The company had revenue of GBX 169 million during the quarter. On average, sell-side analysts predict that 4basebio PLC will post -3.43 earnings per share for the current year.

Insider Activity

In other news, insider Amy Walker bought 1,863 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average cost of GBX 509 per share, for a total transaction of £9,482.67. Corporate insiders own 12.08% of the company’s stock.

4basebio Company Profile

(Get Free Report)

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.